Z
9.75
0.18 (1.88%)
| Penutupan Terdahulu | 9.57 |
| Buka | 9.54 |
| Jumlah Dagangan | 157,037 |
| Purata Dagangan (3B) | 293,752 |
| Modal Pasaran | 407,462,240 |
| Harga / Jualan (P/S) | 4.56 |
| Harga / Buku (P/B) | 1.11 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2024 |
| EPS Cair (TTM) | -3.09 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.32% |
| Nisbah Semasa (MRQ) | 4.82 |
| Aliran Tunai Operasi (OCF TTM) | -33.62 M |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Zenas BioPharma, Inc. | - | - |
AISkor Stockmoo
1.6
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.63 |
|
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 24.78% |
| % Dimiliki oleh Institusi | 65.08% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Sr One Capital Management, Lp | 30 Sep 2024 | 4,911,539 |
| Nvp Associates, Llc | 30 Sep 2024 | 1,838,482 |
| Novo Holdings A/S | 30 Sep 2024 | 1,150,000 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 45.00 (Guggenheim, 361.54%) | Beli |
| Median | 35.00 (258.97%) | |
| Rendah | 27.00 (Citigroup, 176.92%) | Beli |
| Purata | 34.40 (252.82%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 14.20 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 16 Dec 2024 | 30.00 (207.69%) | Beli | 8.77 |
| Morgan Stanley | 11 Dec 2024 | 35.00 (258.97%) | Beli | 9.16 |
| 08 Oct 2024 | 40.00 (310.26%) | Beli | 17.69 | |
| Citigroup | 08 Oct 2024 | 27.00 (176.92%) | Beli | 17.69 |
| Guggenheim | 08 Oct 2024 | 45.00 (361.54%) | Beli | 17.69 |
| Jefferies | 08 Oct 2024 | 35.00 (258.97%) | Beli | 17.69 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |